Cantor Fitzgerald announced on Tuesday that Eric Schmidt and Josh Schimmer are joining its biotech research group.

康托·菲茨杰拉德（Cantor Fitzgerald）星期二宣布埃里克·施密特（Eric Schmidt）和乔什·希默（Josh Schimmer）正在加入其生物技术研究小组。

Schimmer is a former senior managing director of Evercore ISI’s biotech research team, while Schmidt was most recently the chief financial officer at cell therapy company Allogene. Prior to Allogene, Schmidt spent 20 years as an analyst at Cowen.

Schimmer是Evercore ISI生物技术研究团队的前高级总经理，而Schmidt最近是cell therapy company Allogene的首席财务官。在异基因之前，施密特在Cowen担任分析师20年。

Endpoints chatted briefly over Zoom with Schmidt about Cantor’s biotech equity research and the future of cell and gene therapy.

端点与施密特简要讨论了坎托的生物技术股权研究以及细胞和基因治疗的未来。

Unlock this article instantly by becoming a free subscriber.

成为免费用户立即解锁本文。

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

您可以每月访问免费文章，还可以自定义每周发送到框中的新闻通讯，包括新闻报道。

SIGN UP

注册

LOG IN

登录

BECOME A PREMIUM SUBSCRIBER

成为高级用户